Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M59,882Revenue $M100,887Net Margin (%)2.0Z-Score3.2
Enterprise Value $M71,627EPS $2.6Operating Margin %3.6F-Score8
P/E(ttm))31.0Cash Flow Per Share $3.6Pre-tax Margin (%)3.0Higher ROA y-yY
Price/Book3.010-y EBITDA Growth Rate %24.4Quick Ratio0.5Cash flow > EarningsY
Price/Sales0.65-y EBITDA Growth Rate %20.7Current Ratio0.6Lower Leverage y-yY
Price/Cash Flow14.9y-y EBITDA Growth Rate %5.0ROA % (ttm)3.7Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)9.6Less Shares Outstanding y-yY
Payout Ratio %0Shares Outstanding M727ROI % (ttm)3.5Gross Margin Increase y-yY

Gurus Latest Trades with ESRX

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
ESRXGlenn Greenberg 2014-12-31 Reduce-2.33%$69.65 - $85.96
($78.34)
$ 82.385%Reduce -17.94%4,088,652
ESRXChris Davis 2014-12-31 Add0.65%$69.65 - $85.96
($78.12)
$ 82.385%Add 22.09%13,002,699
ESRXWallace Weitz 2014-12-31 Reduce-0.19%$69.65 - $85.96
($78.12)
$ 82.385%Reduce -5.17%1,684,987
ESRXScott Black 2014-12-31 Reduce-0.14%$69.65 - $85.96
($78.12)
$ 82.385%Reduce -11.14%115,057
ESRXMario Gabelli 2014-12-31 Reduce-0.04%$69.65 - $85.96
($78.12)
$ 82.385%Reduce -45.53%134,879
ESRXJoel Greenblatt 2014-12-31 Reduce-0.02%$69.65 - $85.96
($78.34)
$ 82.385%Reduce -46.28%25,788
ESRXRay Dalio 2014-12-31 Add0.02%$69.65 - $85.96
($78.12)
$ 82.385%Add 54.02%77,262
ESRXWarren Buffett 2014-12-31 Sold Out -0.03%$69.65 - $85.96
($78.34)
$ 82.385%Sold Out0
ESRXGlenn Greenberg 2014-09-30 Add0.79%$65.6 - $75.51
($71.37)
$ 82.3813%Add 6.50%4,982,726
ESRXJoel Greenblatt 2014-09-30 Reduce-0.15%$65.6 - $75.51
($71.37)
$ 82.3813%Reduce -78.07%48,001
ESRXCharles Brandes 2014-09-30 Add0.14%$65.6 - $75.51
($71.37)
$ 82.3813%Add 7.22%2,253,914
ESRXMario Gabelli 2014-09-30 Reduce-0.04%$65.6 - $75.51
($71.37)
$ 82.3813%Reduce -32.33%247,614
ESRXRay Dalio 2014-09-30 Add0.01%$65.6 - $75.51
($71.37)
$ 82.3813%Add 33.22%50,162
ESRXGlenn Greenberg 2014-06-30 Add3.17%$66.17 - $76.08
($70.4)
$ 82.3815%Add 31.94%4,678,694
ESRXCharles Brandes 2014-06-30 Buy 1.8%$66.17 - $76.08
($70.4)
$ 82.3815%New holding2,102,152
ESRXWallace Weitz 2014-06-30 Add1.1%$66.17 - $76.08
($70.4)
$ 82.3815%Add 43.89%1,742,324
ESRXDodge & Cox 2014-06-30 Add0.42%$66.17 - $76.08
($70.4)
$ 82.3815%Add 54.28%17,874,930
ESRXScott Black 2014-06-30 Reduce-0.32%$66.17 - $76.08
($70.4)
$ 82.3815%Reduce -22.86%129,139
ESRXJoel Greenblatt 2014-06-30 Add0.17%$66.17 - $76.08
($70.4)
$ 82.3815%Add 682.51%218,877
ESRXHOTCHKIS & WILEY 2014-06-30 Add0.16%$66.17 - $76.08
($70.4)
$ 82.3815%Add 50.52%1,918,200
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

ESRX is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


ESRX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Stettin Glen D.Sr. VP, Clin. Res. & New Sol. 2015-03-02Sell2,674$84.39-1.66view
Stettin Glen D.Sr. VP, Clin. Res. & New Sol. 2015-02-25Sell27,603$87.55-5.21view
Ebling Keith J.Exec. VP and General Counsel 2014-12-02Sell10,000$84.25-1.5view
Miller Steven BSr. VP & Chief Med. Officer 2014-12-01Sell4,896$83.57-0.69view
Stettin Glen D.Sr. VP, Clin. Res. & New Sol. 2014-11-28Sell10,800$82.960.04view
MAC MAHON THOMAS PDirector 2014-11-21Sell12,694$80.932.55view
Stettin Glen D.Sr. VP, Clin. Res. & New Sol. 2014-11-21Sell10,874$81.51.83view
PARKER JOHN ODirector 2014-11-17Sell25,822$78.755.38view
Breen Maura CDirector 2014-11-07Sell13,128$77.86.67view
IGNACZAK EDWARD BEVP 2014-09-05Sell9,886$75.2810.24view

Press Releases about ESRX :

    Quarterly/Annual Reports about ESRX:

    News about ESRX:

    Articles On GuruFocus.com
    Analyzing Steven Romick's New Buys: Express Scripts (ESRX) Mar 19 2015 
    Rolfe Adds One Company to Portfolio in Fourth Quarter Feb 18 2015 
    Analyzing Needham Growth Fund's Pick: Express Scripts (ESRX) Feb 13 2015 
    Analyzing Needham Growth Fund's Pick: CarMax (KMX) Feb 13 2015 
    Gilead Sciences Offering Fresh Wave Of Competition To AbbVie’s Viekira Pak Feb 06 2015 
    Thornburg Value Fund Q4 2014 Commentary Feb 04 2015 
    Weitz Value Fund Q4 2014 Commentary Jan 26 2015 
    Wedgewood Partners Q4 2014 Client Letter - '2015 - Groundhog Day or Wizard of Oz?' Jan 22 2015 
    Has Gilead Sciences Been Able To Maintain Its Lead Run In The Face Of Competition? Jan 22 2015 
    Steven Romick Buys 7 US and International Stocks in Q4 Jan 14 2015 

    More From Other Websites
    Biotech's rough ride over? Mar 26 2015
    The Scariest Health Care Statistic of 2014 Mar 18 2015
    Zacks Industry Outlook Highlights: Orexigen, MannKind, Amgen, Medivation and Express Scripts - Press... Mar 18 2015
    Critical Reports Mount On Hepatitis C Pill Costs Mar 17 2015
    Prescription drug spending has gone through the roof — and now we know why Mar 16 2015
    Buy These Stocks to Avoid Dollar Damage, Goldman Sachs Says Mar 16 2015
    These cholesterol drugs stocks are poised to move Mar 13 2015
    CVS: Copycat drugs may bring price cuts of 40-50% Mar 12 2015
    Express Scripts Issues Report on Prescription Drug Spending - Analyst Blog Mar 11 2015
    Wolfe Research Analysts: 'Good News ... More Drugs!' Mar 11 2015
    CNBC update: Prescription drug spending up Mar 10 2015
    Drug Spending Accelerated In 2014: Express Scripts Mar 10 2015
    Hepatitis C Meds Absorb Most Of 13% Jump In Drug Spending Mar 10 2015
    Hepatitis C drugs drive 13% jump in medicine spending Mar 10 2015
    Report: Specialty drugs drive prescription spending jump Mar 10 2015
    What!?! Specialty drug spending jumps 31% Mar 10 2015
    Hepatitis C pills drive surge in U.S. drug costs -report Mar 10 2015
    U.S. Prescription Drug Spending Increased 13.1 Percent in 2014, Driven by Hepatitis C and Compounded... Mar 10 2015
    Prescription drug prices rising: Report Mar 10 2015
    U.S. Prescription Drug Spending Increased 13.1 Percent in 2014, Driven by Hepatitis C and Compounded... Mar 10 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    Srichardson
    ReplySrichardson - 7 months ago
    How do you see the % of Total Asset for a position in a guru portfolio?
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK